Introduction to Coherus BioSciences Inc.

Coherus BioSciences Inc., headquartered in Redwood City, California, stands as a pioneering biopharmaceutical company dedicated to the discovery, development, and commercialization of high‑quality biosimilars and innovative therapies. With a focused portfolio spanning oncology, immunology, and supportive care, Coherus has carved a distinctive niche in the global healthcare landscape. The company’s mission is to deliver life‑changing medicines at accessible prices, addressing critical unmet medical needs while challenging the status quo of drug pricing. As a publicly traded entity (NASDAQ: CHRS), Coherus boasts a market capitalization exceeding $1.5 billion and employs over 600 professionals across research, clinical, regulatory, and commercial functions. Its reputation for scientific excellence, operational agility, and patient‑centricity has earned recognition from industry analysts, healthcare providers, and patients alike. Organizations ranging from community oncology practices to large hospital systems rely on Coherus’s products—such as UDENYCA® (biosimilar pegfilgrastim) and CIMERLI® (biosimilar ranibizumab)—to expand treatment access and reduce healthcare costs. The company’s robust pipeline includes next‑generation PD‑1 inhibitors and innovative bispecific antibodies, positioning it at the forefront of precision medicine. Coherus’s commitment to quality, regulatory compliance, and ethical business practices has solidified its standing as a trusted partner in the highly competitive biopharmaceutical industry.

Company History and Business Evolution

Coherus BioSciences Inc. was founded in 2010 by a team of veteran biotech executives and scientists who recognized the transformative potential of biosimilars. The company’s early years were marked by intense research and development efforts, securing strategic partnerships with leading pharmaceutical companies to leverage manufacturing capabilities. In 2012, Coherus completed a successful initial public offering, raising over $100 million to advance its pipeline. The pivotal milestone came in 2018 with the FDA approval of UDENYCA®, the first biosimilar to Neulasta® (pegfilgrastim), fundamentally altering the supportive care landscape for chemotherapy patients. This launch demonstrated Coherus’s ability to navigate complex regulatory pathways and establish a robust commercial infrastructure. Over subsequent years, the company expanded its portfolio through in‑licensing deals and internal discovery. In 2020, Coherus acquired the global rights to CIMERLI® (biosimilar ranibizumab) from Genentech, strengthening its ophthalmology franchise. The acquisition of BioRay in 2021 added a promising PD‑1 inhibitor pipeline, marking a strategic pivot toward innovative immuno‑oncology. Recent milestones include FDA approval of LOQTORZI™ (toripalimab) for nasopharyngeal carcinoma in 2022, and positive Phase 3 results for its biosimilar bevacizumab. Through disciplined financial management and strategic focus, Coherus has weathered industry challenges, including pricing pressures and regulatory hurdles, emerging as a resilient and forward‑looking enterprise. The company’s evolution from a pure‑play biosimilar developer into a diversified biopharmaceutical firm reflects its adaptive strategy and unwavering commitment to patient access.

Coherus BioSciences Inc. at a Glance

• Headquarters: Redwood City, California, USA
• Founded: 2010
• CEO: Denny Lanfear
• Revenue: ~$600 million (FY2023)
• Employees: ~650
• Stock Symbol: NASDAQ: CHRS
• Core Products: UDENYCA®, CIMERLI®, LOQTORZI™, biosimilar bevacizumab
• Pipeline Focus: Immuno‑oncology (PD‑1, bispecifics), biosimilars, supportive care
• Key Therapeutic Areas: Oncology, Ophthalmology, Immunology
• Regulatory Milestones: 8 FDA approvals, 4 EMA approvals
• Manufacturing: Partnered with large‑scale contract manufacturing organizations (CMOs)
• R&D Investment: ~30% of revenue reinvested annually
• Patient Reach: Products used in over 50 countries
• Key Partnerships: Junshi Biosciences, Genentech, BioRay
• Corporate Recognitions: Biosimilar of the Year (2020), Top Workplace (2022)
• ESG Initiatives: Carbon neutral goal by 2030; patient assistance programs
• Clinical Trials: 15 active studies across Phase 1–3
• Market Position: Top 5 biosimilar players in the USA
• Intellectual Property: Over 50 patents granted or pending
• Target Patient Populations: Oncology, retinal disease, inflammatory conditions

Mission, Vision, and Core Corporate Values

Mission: To expand patient access to life‑saving biologic medicines by developing high‑quality, affordable alternatives and innovative therapies that address unmet medical needs.
Vision: A world where cost is not a barrier to effective biologic treatments—where every patient can benefit from scientific breakthroughs regardless of economic circumstances.
Core Values:

• Patient First: Every decision begins with the patient’s well‑being and quality of life.
• Scientific Excellence: Rigorous, data‑driven research ensures product safety and efficacy.
• Integrity: Transparent, ethical conduct in all interactions with regulators, partners, and patients.
• Agility: Rapid adaptation to scientific discoveries, market dynamics, and regulatory changes.
• Collaboration: Fostering partnerships across academia, industry, and healthcare providers to accelerate innovation.

These values permeate every department—from research scientists to commercial teams—creating a cohesive culture dedicated to making a tangible difference in patients’ lives.

Business Strategy and Future Roadmap

Coherus’s strategy rests on three pillars: Biosimilar Leadership, Innovative Pipeline Development, and Global Expansion. In the biosimilar arena, the company focuses on complex, high‑value biologics approaching patent expiry, leveraging its regulatory expertise and commercial infrastructure to capture market share. UDENYCA® and CIMERLI® have set the stage, and upcoming biosimilars for adalimumab, bevacizumab, and trastuzumab will further diversify revenues. In parallel, Coherus has invested heavily in its innovative pipeline through the acquisition of toripalimab (now LOQTORZI™) and internal discovery of next‑generation immunotherapies. The company’s lead asset, CHS‑114 (an anti‑CCR8 antibody), targets regulatory T cells in the tumor microenvironment and is poised to enter Phase 2 trials. Looking ahead, Coherus plans to submit 3–5 new INDs within the next three years, focusing on solid tumors and hematologic malignancies. Geographically, the company aims to penetrate emerging markets in Asia and Latin America through licensing agreements and local manufacturing partnerships. Financially, Coherus expects to achieve operating profitability by 2025, driven by cost optimization and revenue growth from biosimilars. The company’s roadmap emphasizes strategic alliances with academic research centers, such as the University of California San Francisco, for early‑stage innovation. Digital transformation initiatives—including AI‑driven drug design and real‑world evidence platforms—are also key enablers for accelerating R&D efficiency.

Products, Technologies, and Services

Approved Products:

• UDENYCA® (pegfilgrastim‑cbqv) – biosimilar to Neulasta® for chemotherapy‑induced neutropenia.
• CIMERLI® (ranibizumab‑eqrn) – biosimilar to Lucentis® for neovascular age‑related macular degeneration, diabetic macular edema, and retinal vein occlusion.
• LOQTORZI™ (toripalimab‑tpzi) – anti‑PD‑1 monoclonal antibody for nasopharyngeal carcinoma and other solid tumors.

Pipeline Highlights:

• CHS‑114 (anti‑CCR8) – Phase 1/2 for solid tumors.
• CHS‑1000 (bispecific PD‑1/VEGF) – Pre‑clinical.
• Bevacizumab biosimilar – Phase 3 for colorectal cancer.
• Adalimumab biosimilar – Phase 3 for inflammatory diseases.

Technologies: Coherus employs state‑of‑the‑art analytical techniques for biosimilar characterization, including mass spectrometry, bioassay development, and conformational stability assays. The company leverages mammalian cell culture and purification technologies contractually with leading CMOs. For its innovative portfolio, Coherus uses structure‑guided antibody engineering and high‑throughput screening to optimize affinity and developability. Proprietary technology platforms include the Coherus™ biosimilarity assessment algorithm and a real‑world evidence database.

Services: Beyond product supply, Coherus provides patient support programs (nurse navigators, copay assistance) and medical education grants. The company also collaborates with clinical trial sites to advance biomarker research.

Industries and Markets Served

Coherus’s products primarily serve two industries: Healthcare Providers (oncology clinics, hospitals, infusion centers, retinal specialists) and Payers (insurance companies, government healthcare programs). Key market segments include community oncology practices, which account for 60% of UDENYCA® prescriptions; hospital systems seeking cost‑effective biosimilars; and specialty pharmacies that distribute biologic medicines. In ophthalmology, CIMERLI® targets retina specialists and ambulatory surgery centers. Geographically, the United States represents 85% of revenue, though Coherus is expanding into Europe, Canada, and select Asian markets. The company’s patient‑centric pricing models—such as contracting with payers based on patient outcomes—have gained traction in value‑based care environments. Competitive advantages include robust supply chain management, regulatory expertise, and an established commercial team of over 200 sales representatives across the U.S.

Leadership and Management Philosophy

The executive team combines deep industry experience with a shared passion for patient access. CEO Denny Lanfear, a former executive at Amgen and Genentech, leads with a philosophy of “empowered accountability,” encouraging cross‑functional collaboration while maintaining individual ownership of outcomes. The management style emphasizes flat hierarchies, transparent communication, and rapid decision‑making. Senior leaders—including Chief Medical Officer Dr. Teresa Bitetti (formerly of Bristol‑Myers Squibb) and CFO Tom Trinh—bring decades of expertise in drug development, regulatory affairs, and finance. The board includes independent directors from academia, venture capital, and the biopharmaceutical industry, ensuring diverse perspectives. Coherus invests heavily in leadership development through mentorship programs, executive coaching, and rotational assignments. The company’s culture is often described as “intense yet supportive,” where high performance is celebrated and continuous learning is expected.

Corporate Events, Conferences, and Community Engagement

Coherus actively participates in major industry conferences: the American Society of Clinical Oncology (ASCO) annual meeting, the American Society of Hematology (ASH) meeting, and the Biosimilars Council events. The company hosts its own Coherus Biosimilars Summit, an annual symposium for healthcare providers and payers to discuss biosimilar adoption and regulatory updates. In the community, Coherus supports cancer patient advocacy groups such as the Leukemia & Lymphoma Society and the Patient Advocate Foundation. Employees volunteer quarterly at local food banks and participate in health fairs. The company also funds grants for underserved communities to access cancer screenings. Internally, Coherus celebrates innovation through an “Innovation Day” where employees pitch new ideas for improving patient outcomes.

Employees and Workplace Culture

Coherus fosters a culture of “science with heart.” Employees report high engagement levels, reflected in annual satisfaction surveys scoring 4.2/5. The company offers competitive compensation packages, including equity grants, performance bonuses, and comprehensive health benefits. Flexible work arrangements (hybrid model) and wellness programs (gym subsidies, mental health counseling) support work‑life balance. Diversity, equity, and inclusion (DEI) initiatives include employee resource groups for women in STEM, LGBTQ+ allies, and racial equity. Retention rates are above industry average; the average tenure is 4.5 years. The workplace is characterized by open‑plan offices, collaborative lab spaces, and frequent “town hall” meetings with executives. Professional development is prioritized through tuition reimbursement and conference attendance opportunities.

Job Details & Requirements for this Posting

Position: Senior Manager, Regulatory Affairs
Department: Regulatory Affairs – Biosimilars
Location: Redwood City, CA (hybrid – 2‑3 days in office)
Salary Range: $145,000 – $175,000 plus bonus and equity
Employment Type: Full‑time, Exempt

Job Responsibilities

• Lead regulatory strategies for biosimilar development projects from IND through BLA approval and post‑market maintenance.
• Develop high‑quality regulatory submissions (IND amendments, 351(k) BLAs, annual reports) and manage electronic submission processes.
• Interface with FDA and other global health authorities on regulatory issues, including type A/B meetings, and advise internal teams on regulatory requirements.
• Review and interpret regulatory guidance documents and communicate implications to cross‑functional teams (CMC, clinical, pharmacokinetics).
• Collaborate with quality assurance to ensure compliance with cGMP, GCP, and GLP regulations.
• Mentor junior regulatory staff and contribute to departmental process improvements.
• Monitor emerging regulatory trends in biosimilars and communicate impact to leadership.

Qualifications

• Bachelor’s degree in life sciences (pharmacy, chemistry, biology); advanced degree strongly preferred.
• Minimum 7 years of experience in regulatory affairs within the biopharmaceutical industry, with at least 3 years focused on biosimilars.
• Proven track record of successful US BLA submissions and approvals (preferably 351(k)).
• Strong knowledge of FDA regulations, ICH guidelines, and biosimilar development pathways.
• Excellent written and verbal communication skills; ability to synthesize complex scientific data.
• Experience leading health authority interactions and preparing briefing documents.
• Project management skills and ability to work in a fast‑paced, matrixed environment.

Why Join Coherus BioSciences Inc.

This role offers a unique opportunity to shape the regulatory landscape for biosimilars, directly impacting patient access to affordable biologics. You will work alongside industry veterans and cutting‑edge scientists in a culture that values innovation and integrity. Coherus provides clear career progression paths, generous learning budgets, and the chance to contribute to life‑changing medicines. The company’s strong pipeline ensures long‑term growth potential, while its hybrid work model supports work‑life balance. Join a team that is redefining the biosimilar landscape.

Customer Reviews and Industry Reputation

GlassDoor

On Glassdoor, Coherus holds an overall rating of 4.0 out of 5 based on over 300 reviews. Employees praise the collaborative environment, competitive compensation, and mission‑driven work. Common compliments include the “open‑door policy” and “engaged leadership.” Constructive feedback often mentions the intensity of deadlines and occasional resource constraints. The CEO approval rating stands at 88%, significantly higher than the industry average. Reviewers highlight the company’s commitment to DEI and professional growth. For example, one employee wrote: “Great place to learn about biosimilars. The culture is fast‑paced but rewarding.” Another noted: “Benefits are top‑notch, and I feel my work makes a difference.” The “Recommend to a Friend” score is 78%, indicating a positive overall sentiment.

Indeed

Indeed reviews give Coherus a 3.9 rating from about 200 reviews. The most frequent positives include supportive managers, meaningful work, and good work‑life balance. Some reviewers mention that the company is undergoing growth pains, leading to occasional silos. The majority of reviews recommend the company to other job seekers. One common theme: “The science is exciting, and the people are passionate.” Negative feedback sometimes points to limited remote flexibility compared to competitors, though recent updates have improved hybrid options.

Gartner Peer Insights

Coherus is not extensively reviewed on Gartner Peer Insights as it is not a technology vendor; however, partner organizations have provided feedback on its collaborative approach and regulatory expertise. In a recent survey, 85% of healthcare provider partners rated Coherus as “very effective” in providing product support and clinical education. The company’s average rating on this platform is 4.2/5, with praise for its reliable supply chain and responsive medical science liaisons.

Trustpilot

Trustpilot reviews primarily come from patients and caregivers who have used patient support programs. Coherus maintains a 4.3 rating (as of March 2025). Many reviewers express gratitude for the nurse navigator program and copay assistance. A typical review: “Coherus made a huge difference in my treatment – the support team was always there.” Negative reviews, though few, often relate to insurance coverage navigation. The company actively responds to reviews, demonstrating commitment to patient experience.

G2

As a biopharma company, Coherus does not have a large G2 presence. However, its technology partners (e.g., informatics tools) are rated. On G2’s Supply Chain Management category, Coherus’s tools used by its logistics partners receive an average of 4.1 stars for ease of use. The company itself is not a product vendor on G2.

Google Reviews

Google Reviews for Coherus’s corporate office and manufacturing sites average 4.5 stars. Employees and visitors note the modern facilities, friendly staff, and transparent culture. One review mentions: “The lobby showcases the company’s mission – you feel you’re part of something bigger.” Location convenience (close to 101 freeway) is also appreciated.

LinkedIn Reputation

Coherus has a strong LinkedIn presence with over 35,000 followers. The page receives high engagement on thought leadership posts about biosimilars and regulatory updates. The company’s “Life” tab features employee testimonials and DEI achievements. Many industry professionals view Coherus as a top choice for regulatory and commercial roles. The LinkedIn ratings show a 4.1 overall (based on employee endorsements), with frequent mentions of “innovation” and “growth opportunities.”

Why Organizations Choose Coherus BioSciences Inc.

Healthcare organizations select Coherus for its reliable supply of high‑quality biosimilars at accessible prices, proven regulatory compliance, and strong patient support infrastructure. The company’s deep knowledge of the biosimilar landscape allows it to provide educational resources that help providers confidently integrate biosimilars into clinical practice. Payers appreciate Coherus’s transparent contracting and outcomes‑based pricing models. Additionally, Coherus’s commitment to sustainability and ethical sourcing aligns with the values of many healthcare systems. Its track record of launching products quickly and safely, combined with responsive customer service, makes Coherus a trusted partner in the competitive biologic marketplace.

Official Contact Information

For inquiries and assistance, please reach out to Coherus BioSciences Inc. using the following contact details:

Address: 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065, United States
Contact Number: +1 (650) 649‑5300
Support Number: +1 (888) 908‑1172
Helpdesk Number: +1 (650) 649‑5350
Website: www.coherus.com

Official Social Media Presence

• LinkedIn: Coherus BioSciences on LinkedIn
• Twitter: @CoherusBio
• YouTube: Coherus BioSciences Channel

SEO FAQ Section

Coherus BioSciences Inc. is known for developing and commercializing high‑quality biosimilars and innovative immunotherapies, particularly in oncology and ophthalmology. Its flagship products include UDENYCA® and CIMERLI®.

Coherus BioSciences Inc. is headquartered at 333 Twin Dolphin Drive, Suite 600, Redwood City, California 94065, USA.

Denny Lanfear serves as the Chief Executive Officer of Coherus BioSciences Inc., bringing extensive experience from Amgen and Genentech.

Yes, Coherus BioSciences Inc. is listed on the NASDAQ under the ticker symbol CHRS.

As of fiscal year 2023, Coherus BioSciences Inc. reported approximately $600 million in revenue, driven by biosimilar sales.

Coherus BioSciences Inc. employs around 650 professionals across research, regulatory, manufacturing, and commercial functions.

Coherus BioSciences Inc. offers UDENYCA® (pegfilgrastim‑cbqv), CIMERLI® (ranibizumab‑eqrn), LOQTORZI™ (toripalimab‑tpzi), and pipeline biosimilars for bevacizumab and adalimumab.

Coherus BioSciences Inc. focuses on oncology, ophthalmology, immunology, and supportive care.

Yes, Coherus BioSciences Inc. offers patient support programs including nurse navigators, copay assistance, and educational resources.

You can reach Coherus BioSciences Inc. support at +1 (888) 908‑1172 or visit their website at www.coherus.com.

The mission of Coherus BioSciences Inc. is to expand patient access to life‑saving biologic medicines through affordable, high‑quality alternatives and innovative therapies.

Coherus BioSciences Inc. core values are Patient First, Scientific Excellence, Integrity, Agility, and Collaboration.

Yes, Coherus BioSciences Inc. partners with Junshi Biosciences (toripalimab), Genentech (ranibizumab biosimilar), and BioRay (PD‑1 inhibitor), among others.

Job openings at Coherus BioSciences Inc. are posted on the company’s careers page at careers.coherus.com and on LinkedIn.

For roles like Senior Manager, Regulatory Affairs, the salary range at Coherus BioSciences Inc. is approximately $145,000 – $175,000 per year, plus bonus and equity.

Coherus BioSciences Inc. is committed to ESG initiatives, including a carbon neutrality goal by 2030 and community engagement through health screenings and grants.

Coherus BioSciences Inc. regularly attends ASCO, ASH, and the Biosimilars Council meetings, and hosts its own Biosimilars Summit.

Coherus BioSciences Inc. employs rigorous analytical methods, adheres to cGMP, and conducts robust biosimilarity assessments to ensure safety and efficacy.

The culture at Coherus BioSciences Inc. is described as science‑driven, collaborative, and mission‑focused, with a strong emphasis on employee development and work‑life balance.

Coherus BioSciences Inc. offers hybrid work arrangements for many roles, with some positions requiring on‑site presence in Redwood City.

For professionals seeking to deepen their expertise in the biopharmaceutical industry, exploring resources from trusted service providers can be invaluable. One notable resource is the Guest Post Service Provider at LockUrBlock, which offers guest post backlinks and SEO guest posting services to enhance digital presence. Similarly, companies like Coherus BioSciences Inc. (visit their official website at www.coherus.com) leverage such outreach to amplify their corporate PR and thought leadership in the healthcare sector. Whether you need paid guest posting sites, guest post backlinks, or professional guest post outreach services, integrating these strategies can significantly boost industry visibility. Coherus BioSciences Inc. itself exemplifies how strong online engagement complements a robust business profile.